Journal of Clinical Oncology
Articles in this Issue
Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis.
761 Background: Enfortumab vedotin (EV) is an antibody-drug conjugate that binds nectin-4, a cell-adhesion molecule highly expressed in urothelial carcino...
Gut health and prostate cancer: The influence of a specific phytochemical-rich food capsule plus or minus a probiotic/prebiotic blend on symptoms and progression—A randomised, double-blind placebo-controlled trial.
311 Background: The "gut-prostate axis" is increasingly being recognised as an influencer of prostate cancer (PCa) inciden...
Prognostic value of preoperative fibrinogen in metastatic clear cell renal cell carcinoma patients undergoing cytoreductive nephrectomy: A propensity score-matched study.
563 Background: The measurement of serum fibrinogen (FIB) levels is often overlooked in metastatic clear cell renal cell carcinoma (mccRCC). This study ai...
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial.
665 Background: This single-arm phase II trial was conducted to evaluate the efficacy and safety of neoadjuvent disitamab vedotin (DV, a HER2-targetted mo...
Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
802 Background: Detalimogene voraplasmid is a novel, investigational, non-integrating, non-viral gene therapy specifically engineered for intravesical adm...
Clinical characterization and treatment patterns in patients with metastatic hormone-sensitive prostate cancer at three third-level centers of the Mexican Institute of Social Security: A retrospective cohort study.
91 Background: In Latin America, prostate cancer (PC) is the most common cancer among men. Despite efforts in select institutions in Mexico to register an...
Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
TPS295 Background: mCRPC is characterized by an immunosuppressive tumor microenvironment with few intratumoral effector T cells, leading to low response r...
Patient-reported outcome (PRO) assessment and reporting in first-line (1L) locally advanced or metastatic urothelial cancer (la/mUC) clinical trials: Results of a systematic literature review (SLR).
757 Background: Although maintaining health-related quality of life (HRQOL) is a primary goal of advanced cancer care, HRQOL and PROs usually are not meas...
Outcomes with tandem or triplet autologous stem cell transplant for refractory germ cell tumors.
632 Background: While Germ Cell Tumor (GCT) remain highly curable, up to 40% of patients (pts) with intermediate or poor risk advanced GCT will relapse. I...
Primary tumor response to enfortumab vedotin with/without pembrolizumab in patients with upper tract urothelial cancer.
684 Background: Cisplatin-based chemotherapy remains the standard for invasive urothelial cancer (UC) in the perioperative setting. Patients with upper tr...
Examining community social vulnerability domains and influence on treatment selection for men with prostate cancer.
363 Background: For men with clinically localized PCa, treatment selection guided by patient age, comorbidities, and tumor characteristics can offer impro...
Clinical features and prognostic value of CDK12 mutation in prostate cancer patients.
103 Background: Studies have reported that biallelic loss of CDK12 in prostate cancer patients leads to genomic instability and an increase in tandem dupl...
Real world outcomes of <sup>177</sup> Lu-PSMA-617 PSMA in a racially diverse cohort of patients with metastatic castration resistant prostate cancer (mCRPC).
97 Background: 177 Lu-PSMA-617 is approved for treatment of mCRPC based on the VISION trial cohort with limited racial diversity. We analyzed...
Hospitalizations in veterans treated with monotherapy vs combination therapy for metastatic hormone sensitive prostate cancer.
72 Background: Current treatment of metastatic hormone sensitive prostate cancer (mHSPC) includes androgen deprivation therapy (ADT) monotherapy or combin...
Overall survival between veterans with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone with kidney disease.
76 Background: Enzalutamide and abiraterone are androgen receptor pathway inhibitors (ARPIs) used in metastatic castration-resistant prostate cancer (mCRP...
PET imaging for metastatic castration sensitive prostate cancer (mCSPC) for patients with PSA response after systemic therapy: A multicentric ambispective analysis.
37 Background: PET imaging is not recommended for surveillance of mCSPC but it is used by some physicians. Little is known about surveillance for metastat...
Evaluation of the impact on overall survival curves of patients with metastatic castration-sensitive prostate cancer staged with PET-PSMA and classified according to current prognostic criteria by volume and risk.
36 Background: The treatment of metastatic castration-sensitive prostate cancer (mCSPC) has evolved over the years. These therapies are guided by current...
Prevalence of FGFR3 p.Arg248Cys mutation in lynch syndrome associated urothelial carcinoma: A single institution dataset.
858 Background: Patients with Lynch syndrome have an increased risk of developing UC and a relative risk in patient with MSH2 germline impairment of 3,6....
Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial.
310 Background: To determine the potential impact of persistent hypogonadism on overall survival (OS) after prolonged andr...
Comparison of digital pathology AI models, genomics classifier, and clinical variables in predicting progression free survival in TCGA prostate data set.
335 Background: Recent advances in AI have brought innovation to digital pathology problems with H&E whole slide images (WSI). Though some digital pat...
KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101.
594 Background: Kidney injury molecule-1 (KIM-1) is a circulating biomarker for renal cell carcinoma. The JAVELIN Renal 101 trial established avelumab and...
A phase 1, first-in-human, open label, dose escalating study of B440, an oral cancer vaccine using a WT1-expressing <i>Bifidobacterium</i> , in patients with advanced urothelial cancer.
TPS883 Background: B440, an oral cancer therapeutic vaccine, is based on an innovative oral vaccine platform utilizing gut microbiota ( B. lon...
The impact of neoadjuvant therapy on the formation of tertiary lymphatic structures and the distinct prognosis in prostate cancer.
411 Background: This study aims to investigate the characteristics and prognostic predictive efficiency of tertiary lymphoid structures (TLS) in prostate...
Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.
812 Background: Upper Tract Urothelial Carcinoma (UTUC) presents a challenging prognosis even after Radical Nephroureterec...
A phase 1/2 study of detalimogene voraplasmid (EG-70) intravesical monotherapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC).
TPS886 Background: High-risk NMIBC is generally treated with adjuvant intravesical bacille Calmette-Guérin (BCG); however, ~50% of patients experience rec...